Safety and feasibility of talimogene laherparepvec in peritoneal surface malignancies: Results from the TEMPO trial
{{output}}
Peritoneal surface malignancies (PSMs) remain a therapeutic challenge, particularly in patients with unresectable disease who cannot benefit from cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. The Talimogene Laherparepvec for the Treatmen... ...
